Six patients with antineutrophil cytoplasm antibodies-associated vasculitis contracted COVID-19
| Patient | Age | Sex | Induction therapy | Maintenance therapy | Immunsuppression (within the last 6 months) | Admission to hospital | Serum creatinine (mg/dL) before COVID-19 | Hypogammaglobulinaemia | COVID-19 renal outcome | COVID-19 overall outcome | Serum creatinine (mg/dL) after COVID-19 | SARS-CoV-2 antibodies |
| 1 | 72 | M | Yes | – | Cyclophosphamide 3.09 g (3 pulses), rituximab (2×1 g), methylprednisolone (3.06 g) | Yes | 3.30 | Moderate (IgG 336 mg/dL) | AKI (peak creatinine 5.12) | Oxygen supply (max. 4 L), steroids increased | 2.45 | Detectable |
| 2 | 62 | M | – | Yes | Rituximab (1 g) | Yes | 1.19 | Moderate (IgG 409 mg/dL) | AKI (peak creatinine 1.73) | Non-invasive ventilation, remdesivir, dexamethasone, convalescent plasma | 1.38 | Not detectable |
| 3 | 61 | M | – | – | – | No | 1.35 | No (IgG 1150 mg/dL) | – | Home quarantine | 1.29 | – |
| 4 | 80 | F | – | – | – | No | 3.06 | No (IgG 1100 mg/dL) | – | Home quarantine | 2.33 | Detectable |
| 5 | 56 | F | – | – | – | No | 0.86 | No (IgG 705 mg/dL) | – | Home quarantine | 0.84 | Detectable |
| 6 | 39 | F | – | Yes | Rituximab (1 g) | No | 0.75 | No (IgG 1120 mg/dL) | – | Home quarantine | 0.75 | not detectable |
AKI, acute kidney injury; F, female; M, male.